Longboard Pharmaceuticals (LBPH)
(Delayed Data from NSDQ)
$36.83 USD
-1.53 (-3.99%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $36.80 -0.03 (-0.08%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LBPH 36.83 -1.53(-3.99%)
Will LBPH be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for LBPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LBPH
Wall Street Analysts Think Longboard Pharmaceuticals (LBPH) Could Surge 43.7%: Read This Before Placing a Bet
Longboard Pharmaceuticals (LBPH) is on the Move, Here's Why the Trend Could be Sustainable
LBPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
Recent Price Trend in Longboard Pharmaceuticals, Inc. (LBPH) is Your Friend, Here's Why
Longboard Pharma (LBPH) Up on Upbeat Data From Epilepsy Study
Other News for LBPH
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Bexicaserin Shows Promise in Epilepsy Treatment, Justifying Buy Rating for Longboard Pharmaceuticals
Analysts Offer Insights on Healthcare Companies: Longboard Pharmaceuticals (LBPH) and Viridian Therapeutics (VRDN)
Analysts Offer Insights on Healthcare Companies: Zai Lab (ZLAB), Longboard Pharmaceuticals (LBPH) and R1 RCM (RCM)
Longboard Pharmaceuticals Advances with Promising Seizure Treatment Study